HomeAI · summaries
Storia in 8 fonti
Trump announces deal to lower prices for obesity drugs - UPI.com
Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients and those who pay directly.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
ft.com
US to slash prices of obesity drugs offered on Trump website
White House’s landmark deal with Novo Nordisk and Eli Lilly will cut costs from at least $1,000 to about $350
- ·
forbes.com
Trump Says Obesity Drugmakers Will Cut GLP-1 Prices—Medicare Will Cover Some Costs
The deal also means Medicare will start covering obesity drugs for some patients for the first time beginning next year.
- ·
ilsole24ore.com
Trump, accordo per farmaci antiobesità alla portata di tutti
Il presidente, Eli Lilly e Novo Nordisk hanno presentato un accordo per ridurre i prezzi dei popolari farmaci dimagranti Zepbound e Wegovy a base di GLP-1 per i programmi…
- ·
cnbc.com
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
The deals are among the most politically significant announcements to date in the Trump administration's efforts to rein in high U.S. drug costs.
- ·
bbc.com
Trump unveils deals to lower US weight-loss drug prices
US President Donald Trump announces agreements with drug makers Eli Lilly and Novo Nordisk.
- ·
fortune.com
Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic | Fortune
America's waistline may shrink, but its national debt will swell.
- ·
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
The monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage.
- ·
upi.com
Trump announces deal to lower prices for obesity drugs - UPI.com
Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients and those who pay directly.
- ·
aljazeera.com
Weight-loss drug makers announce pricing agreement with Trump
The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.
- ·
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more private insurers to follow suit.